Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MicroRNAs: role and therapeutic targets in viral hepatitis.
van der Ree MH, de Bruijne J, Kootstra NA, Jansen PL, Reesink HW. van der Ree MH, et al. Antivir Ther. 2014;19(6):533-41. doi: 10.3851/IMP2766. Epub 2014 Mar 18. Antivir Ther. 2014. PMID: 24642660 Review.
Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA-122 levels without affecting other microRNAs in plasma.
van der Ree MH, van der Meer AJ, van Nuenen AC, de Bruijne J, Ottosen S, Janssen HL, Kootstra NA, Reesink HW. van der Ree MH, et al. Among authors: van der meer aj, van nuenen ac. Aliment Pharmacol Ther. 2016 Jan;43(1):102-13. doi: 10.1111/apt.13432. Epub 2015 Oct 26. Aliment Pharmacol Ther. 2016. PMID: 26503793 Free article.
Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients.
van der Ree MH, van der Meer AJ, de Bruijne J, Maan R, van Vliet A, Welzel TM, Zeuzem S, Lawitz EJ, Rodriguez-Torres M, Kupcova V, Wiercinska-Drapalo A, Hodges MR, Janssen HL, Reesink HW. van der Ree MH, et al. Among authors: van der meer aj, van vliet a. Antiviral Res. 2014 Nov;111:53-9. doi: 10.1016/j.antiviral.2014.08.015. Epub 2014 Sep 8. Antiviral Res. 2014. PMID: 25218783 Clinical Trial.
Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.
van der Ree MH, de Vree JM, Stelma F, Willemse S, van der Valk M, Rietdijk S, Molenkamp R, Schinkel J, van Nuenen AC, Beuers U, Hadi S, Harbers M, van der Veer E, Liu K, Grundy J, Patick AK, Pavlicek A, Blem J, Huang M, Grint P, Neben S, Gibson NW, Kootstra NA, Reesink HW. van der Ree MH, et al. Among authors: van nuenen ac, van der valk m, van der veer e. Lancet. 2017 Feb 18;389(10070):709-717. doi: 10.1016/S0140-6736(16)31715-9. Epub 2017 Jan 11. Lancet. 2017. PMID: 28087069 Clinical Trial.
Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing.
van der Ree MH, Stelma F, Willemse SB, Brown A, Swadling L, van der Valk M, Sinnige MJ, van Nuenen AC, de Vree JML, Klenerman P, Barnes E, Kootstra NA, Reesink HW. van der Ree MH, et al. Among authors: van nuenen ac, van der valk m. Antiviral Res. 2017 Oct;146:139-145. doi: 10.1016/j.antiviral.2017.08.016. Epub 2017 Aug 24. Antiviral Res. 2017. PMID: 28844749 Free PMC article.
Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti-MicroRNA-122, RG-101.
Stelma F, van der Ree MH, Sinnige MJ, Brown A, Swadling L, de Vree JML, Willemse SB, van der Valk M, Grint P, Neben S, Klenerman P, Barnes E, Kootstra NA, Reesink HW. Stelma F, et al. Among authors: van der ree mh, van der valk m. Hepatology. 2017 Jul;66(1):57-68. doi: 10.1002/hep.29148. Epub 2017 Jun 7. Hepatology. 2017. PMID: 28295463 Free PMC article. Clinical Trial.
34 results